Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
38.29
-0.76 (-1.95%)
At close: Jul 18, 2025, 4:00 PM
38.30
+0.01 (0.03%)
After-hours: Jul 18, 2025, 4:20 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 13 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $68.38, which forecasts a 78.58% increase in the stock price over the next year. The lowest target is $55 and the highest is $82.
Price Target: $68.38 (+78.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 7 | 7 | 8 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +69.76% | Jul 15, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +108.93% | Jun 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +48.86% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $73 → $72 | Strong Buy | Maintains | $73 → $72 | +88.04% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $70 → $75 | Buy | Maintains | $70 → $75 | +95.87% | May 8, 2025 |
Financial Forecast
Revenue This Year
9.69M
Revenue Next Year
31.67M
from 9.69M
Increased by 226.82%
EPS This Year
-4.66
from -3.58
EPS Next Year
-5.06
from -4.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 65.6M | 151.2M | 636.5M |
| Avg | 9.7M | 31.7M | 175.3M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 1,460.4% | 1,909.9% |
| Avg | - | 226.8% | 453.5% |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.58 | -4.26 | -0.77 |
| Avg | -4.66 | -5.06 | -4.82 |
| Low | -4.69 | -5.48 | -6.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.